Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

被引:411
|
作者
Berger, AC
Farma, J
Scott, WJ
Freedman, G
Weiner, L
Cheng, JD
Wang, H
Goldberg, M
机构
[1] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[4] Fox Chase Canc Ctr, Div Biostat, Philadelphia, PA 19111 USA
关键词
D O I
10.1200/JCO.2005.05.017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Attempts to improve survival of patients with esophageal cancer have been made using induction chemoradiotherapy (CRT) followed by surgery. A large single-center experience was reviewed to determine which treatment-related variables could predict survival and recurrence. Patients and Methods All patients undergoing esophagectomy between January 1994 and December 2002 were reviewed, Univariate and multivariate analyses were performed using log-rank and Cox proportional hazards models, and survival curves were estimated using the Kaplan-Meier method. Results Of 171 patients with invasive cancer, 131 (77%) underwent preoperative CRT. The average age was 60 years, and most patients were male (85%). Operations performed included Ivor-Lewis (60%), transhiatal (8%), three-hole (23%), or left thoracoabdominal (8%) esophagectomy. Perioperative mortality rate was 5%. Median overall survival (OS) of the entire group was 33 months, and the 5-year OS rate was 26%. Induction CRT was associated with a 33% 5-year survival rate compared with 11% for surgery alone (P = .43), Patients downstaged to pathologic stage 0 or I had an improved OS and disease-free survival (DFS) compared with those patients who were not downstaged (P = .022). Additionally, the ability to perform an R0 resection was a significant factor for OS and DFS (n = 130; P < .0001 and P < .0002, respectively). Conclusion Response to CRT and the ability to perform an RO resection are associated with significantly improved survival in patients with esophageal carcinoma. (c) 2005 by American Society of Clinical Oncology.
引用
收藏
页码:4330 / 4337
页数:8
相关论文
共 50 条
  • [21] Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy
    Fang, Hsin-Yueh
    Chao, Yin-Kai
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Liu, Yun-Hen
    [J]. DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [22] Complete Pathologic Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma
    Alnaji, Raed M.
    Du, William
    Singla, Smit
    Attwood, Kristopher
    Nava, Hector
    Malhotra, Usha
    Kukar, Moshim
    Hochwald, Steven
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S1159 - S1159
  • [23] Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma
    Alnaji, Raed M.
    Du, William
    Gabriel, Emmanuel
    Singla, Smit
    Attwood, Kristopher
    Nava, Hector
    Malhotra, Usha
    Hochwald, Steven N.
    Kukar, Moshim
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2016, 20 (09) : 1541 - 1546
  • [24] Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma
    Raed M. Alnaji
    William Du
    Emmanuel Gabriel
    Smit Singla
    Kristopher Attwood
    Hector Nava
    Usha Malhotra
    Steven N. Hochwald
    Moshim Kukar
    [J]. Journal of Gastrointestinal Surgery, 2016, 20 : 1541 - 1546
  • [25] Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer
    Haisley, K. R.
    Hart, K. D.
    Nabavizadeh, N.
    Bensch, K. G.
    Vaccaro, G. M.
    Thomas, C. R., Jr.
    Schipper, P. H.
    Hunter, J. G.
    Dolan, J. P.
    [J]. DISEASES OF THE ESOPHAGUS, 2017, 30 (07):
  • [26] Development of a nomogram for the prediction of pathological complete response after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
    Chao, Yin-Kai
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Liu, Yun-Hen
    Wen, Yu-Wen
    [J]. DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [27] Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer
    MacGuill, M.
    Mulligan, E.
    Ravi, N.
    Rowley, S.
    Byrne, P. J.
    Hollywood, D.
    Kennedy, J.
    Keeling, P. N.
    Reynolds, J. V.
    [J]. DISEASES OF THE ESOPHAGUS, 2006, 19 (04) : 273 - 276
  • [28] Esophageal cancer: improved prognosis with neoadjuvant chemoradiotherapy
    Knippen, Stefan
    Duma, Marciana-Nona
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (01) : 86 - 88
  • [29] Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival
    Lutfi, Waseem
    Martinez-Meehan, Deirdre
    Dhupar, Rajeev
    Christie, Neil
    Sarkaria, Inderpal
    Ekeke, Chigozirim
    Baker, Nicholas
    Luketich, James D.
    Okusanya, Olugbenga T.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (04) : 654 - 661
  • [30] Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
    Liu, Jiaqi
    Zeng, Xiaoxiao
    Zhou, Xiaojuan
    Xu, Yong
    Ding, Zhenyu
    Hu, Yang
    Yuan, Yong
    Chen, Longqi
    Wang, Jin
    Lu, You
    Liu, Yongmei
    [J]. ONCOLOGY LETTERS, 2023, 25 (04)